17-Dec-2025
No headlines found.
Globe Newswire (Wed, 3-Dec 4:51 PM ET)
AVITA Medical to Present at the Piper Sandler 37?? Annual Healthcare Conference
Globe Newswire (Mon, 24-Nov 4:15 PM ET)
Globe Newswire (Mon, 10-Nov 5:22 PM ET)
AVITA Medical to Host Investor Webinar Briefing
Globe Newswire (Sun, 9-Nov 5:00 PM ET)
AVITA Medical Reports Third Quarter 2025 Financial Results
Globe Newswire (Thu, 6-Nov 4:05 PM ET)
Globe Newswire (Mon, 3-Nov 8:30 AM ET)
AVITA Medical to Announce Third Quarter 2025 Financial Results
Globe Newswire (Wed, 29-Oct 4:15 PM ET)
Business Wire (Tue, 28-Oct 7:45 PM ET)
AVITA Medical Welcomes Support for RECELL in Burns in Australia
Globe Newswire (Tue, 28-Oct 4:30 PM ET)
PRNewswire (Thu, 23-Oct 2:15 PM ET)
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Avita Medical trades on the NASDAQ stock market under the symbol RCEL.
As of December 17, 2025, RCEL stock price declined to $3.27 with 207,113 million shares trading.
RCEL has a beta of 1.47, meaning it tends to be more sensitive to market movements. RCEL has a correlation of 0.09 to the broad based SPY ETF.
RCEL has a market cap of $99.71 million. This is considered a Micro Cap stock.
Last quarter Avita Medical reported $17 million in Revenue and -$.46 earnings per share. This fell short of revenue expectation by $-11 million and missed earnings estimates by -$.02.
In the last 3 years, RCEL traded as high as $21.70 and as low as $3.25.
The top ETF exchange traded funds that RCEL belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
RCEL has underperformed the market in the last year with a price return of -73.9% while the SPY ETF gained +11.8%. RCEL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.7% and -9.2%, respectively, while the SPY returned +2.0% and -1.5%, respectively.
RCEL support price is $3.21 and resistance is $3.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCEL shares will trade within this expected range on the day.
